利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.031 秒)

    TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    5.
    发明公开
    TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
    三唑并吡啶化合物及其使用方法

    公开(公告)号：EP3265464A1

    公开(公告)日：2018-01-10

    申请号：EP16707140.6

    申请日：2016-03-02

    申请人： F. Hoffmann-La Roche AG

    发明人： CHENG, Yun-Xing ,  GOODACRE, Simon Charles ,  LI, Wei ,  RAY, Nicholas Charles ,  ZAK, Mark Edward

    IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P29/00

    CPC分类号： C07D471/04 ,  C07D471/10

    摘要： Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.

    TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    9.
    发明公开
    TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF 审中-公开
    四氢吡啶并[3,4-b]吲哚雌激素受体调节剂及其应用

    公开(公告)号：EP3233852A1

    公开(公告)日：2017-10-25

    申请号：EP15810660.9

    申请日：2015-12-17

    申请人： F. Hoffmann-La Roche AG

    发明人： GOODACRE, Simon Charles ,  LABADIE, Sharada ,  LIANG, Jun ,  ORTWINE, Daniel Fred ,  RAY, Nicholas Charles ,  WANG, Xiaojing ,  ZBIEG, Jason ,  ZHANG, Birong

    IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P35/00

    摘要： Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

    摘要翻译： 本文描述了具有式（I）结构的雌激素受体调节活性或功能的四氢吡啶并[3,4-b]吲哚-1-基化合物及其立体异构体，互变异构体或药学上可接受的盐，并且具有取代基和结构 在此描述的特征。 还描述了包含式（I）化合物的药物组合物和药物，以及单独使用这种雌激素受体调节剂并与其他治疗剂组合使用以治疗介导或依赖于雌激素受体的疾病或病症的方法。